Greece to Spend 780 Mln Euros to Protect Marine Biodiversity, Says PM

Plastic waste is pictured at the bottom of the sea, off the island of Andros, Greece, July 20, 2019. (Reuters)
Plastic waste is pictured at the bottom of the sea, off the island of Andros, Greece, July 20, 2019. (Reuters)
TT

Greece to Spend 780 Mln Euros to Protect Marine Biodiversity, Says PM

Plastic waste is pictured at the bottom of the sea, off the island of Andros, Greece, July 20, 2019. (Reuters)
Plastic waste is pictured at the bottom of the sea, off the island of Andros, Greece, July 20, 2019. (Reuters)

Greece is pushing ahead with 21 initiatives worth 780 million euros ($830.9 million) to protect marine biodiversity and tackle coastal pollution, Prime Minister Kyriakos Mitsotakis said on Monday ahead of an international conference.

Greece, which includes thousands of islands and which has the longest Mediterranean coastline of any littoral state, said last week it plans to create two marine parks, one in the Ionian Sea and one in the Aegean Sea, as part of the initiatives.

"Quietly but methodically, Greece is playing a leading role in the defense against dramatic climate changes, which are proven to affect every region and every activity," Mitsotakis said in an article published in Kathimerini newspaper.

Greece plans to present its national strategy on marine biodiversity protection at the "Our Ocean" conference, which Athens will host this year and which will be attended by about 120 countries.

More than 400 new commitments amounting to $10 billion will be announced during the conference, said a government official, speaking on condition of anonymity.

The European Union's Copernicus Climate Change Service said last month that ocean temperatures hit a record high in February, in a dataset that goes back to 1979. Overfishing and plastic pollution are also major threats to oceans.

Plastics entering the world's oceans could nearly triple by 2040 if no further action is taken, research has shown.

Greece wants to reduce plastic litter in the water by 50% and microplastics by 30% by 2030, the government official said.

The Greek marine parks, whose boundaries will be defined after scientific research by early 2025, will cover 32% of Greece's waters, Mitsotakis said. Greece has legislated the expansion of marine protected areas to 30% of its territorial waters by 2030.

The plan for a marine park in the Aegean Sea has irritated neighboring Türkiye, which said last week that it was not willing to accept a possible "fait accompli on geographical features whose status is disputed". In response, Greece accused Türkiye of "politicizing a purely environmental issue".

NATO allies Greece and Türkiye have long been at odds over a range of issues including maritime boundaries and claims over their continental shelves in the Mediterranean.

Mitsotakis said other initiatives underway include campaigns to curb plastic pollution, constructing charging stations at 12 ports for electric vessels and setting up a monitoring system for protected marine areas because fishing practices that damage the seabed will be banned. Greece wants to ban bottom trawling in all marine protected areas by 2030, the official said.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”